{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:14:52Z","timestamp":1791422092183,"version":"4.3.3"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.blre.2011.01.005","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T04:15:33Z","timestamp":1296792933000},"page":"107-112","source":"Crossref","is-referenced-by-count":75,"title":["Plasma cell leukemia"],"prefix":"10.1016","volume":"25","author":[{"given":"Flavio","family":"Albarracin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2011.01.005_bb0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma cell leukemia. Report on 17 cases","volume":"133","author":"Kyle","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2011.01.005_bb0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/0002-9343(87)90942-9","article-title":"Plasma cell leukemia: an evaluation of response to therapy","volume":"83","author":"Noel","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2011.01.005_bb0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"Criteria for the classification of monoclonal gammopathies","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0020","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","article-title":"Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia","volume":"13","author":"Blade","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2011.01.005_bb0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00277-005-0054-4","article-title":"Plasma cell leukemia: a rare condition","volume":"85","author":"Jimenez-Zepeda","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10552-007-9097-2","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.blre.2011.01.005_bb0035","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.01.005_bb0040","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garcia-Sanz","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1991.tb07975.x","article-title":"Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies","volume":"77","author":"San Miguel","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11864-001-0034-4","article-title":"Plasma cell leukemia","volume":"2","author":"Hayman","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.blre.2011.01.005_bb0055","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood.V84.8.2597.2597","article-title":"Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells","volume":"84","author":"Pellat-Deceunynck","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0060","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.V97.3.822","article-title":"Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique","volume":"97","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/10428199609067575","article-title":"Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia","volume":"21","author":"Taniwaki","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.01.005_bb0070","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2011.01.005_bb0075","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.bmt.1705131","article-title":"Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation","volume":"36","author":"Chang","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2011.01.005_bb0080","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0085","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2006.06325.x","article-title":"Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation","volume":"135","author":"Chang","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0090","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.01.005_bb0095","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2141.2007.06750.x","article-title":"Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma","volume":"139","author":"Chang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0105","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.leukres.2008.06.027","article-title":"Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia","volume":"33","author":"Chang","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2011.01.005_bb0115","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.leu.2404524","article-title":"Clinical significance of TP53 mutation in myeloma","volume":"21","author":"Chng","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.01.005_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-4608(03)00233-4","article-title":"Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia","volume":"148","author":"Lloveras","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.blre.2011.01.005_bb0130","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0135","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","article-title":"The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2","volume":"17","author":"Stott","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2011.01.005_bb0140","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1038\/sj.onc.1205359","article-title":"Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors","volume":"21","author":"Eymin","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2011.01.005_bb0145","first-page":"2816","article-title":"p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2","volume":"61","author":"Esteller","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2011.01.005_bb0150","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1073\/pnas.101617298","article-title":"Selective association of the methyl-CpG binding protein MBD2 with the silent p14\/p16 locus in human neoplasia","volume":"98","author":"Magdinier","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2011.01.005_bb0155","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.V75.8.1684.1684","article-title":"The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing","volume":"75","author":"Ahuja","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.01.005_bb0160","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/humu.1177","article-title":"High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis","volume":"18","author":"Bezieau","year":"2001","journal-title":"Hum Mutat"},{"key":"10.1016\/j.blre.2011.01.005_bb0165","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/10428190500300969","article-title":"N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma","volume":"47","author":"Ortega","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.01.005_bb0170","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cncr.21687","article-title":"K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements","volume":"106","author":"Liang","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.01.005_bb0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2141.1998.00700.x","article-title":"Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases","volume":"101","author":"Fonseca","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0165-4608(97)00469-X","article-title":"Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant","volume":"104","author":"Lai","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.blre.2011.01.005_bb0185","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb05114.x","article-title":"Primary plasma cell leukaemia","volume":"88","author":"Dimopoulos","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0190","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/cncr.22700","article-title":"Efficacy and safety of bortezomib in patients with plasma cell leukemia","volume":"109","author":"Musto","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.01.005_bb0195","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1080\/10428190701361851","article-title":"Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia","volume":"48","author":"Benson","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.01.005_bb0200","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.leukres.2008.03.013","article-title":"Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia","volume":"32","author":"Musto","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2011.01.005_bb0205","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/10428190290006143","article-title":"Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia","volume":"43","author":"Johnston","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.01.005_bb0210","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000069284","article-title":"Thalidomide administration for the treatment of resistant plasma cell leukemia","volume":"109","author":"Tsiara","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0215","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.thj.6200375","article-title":"Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report","volume":"5","author":"Wohrer","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.blre.2011.01.005_bb0220","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1046\/j.1365-2141.2002.03537_4.x","article-title":"Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma","volume":"117","author":"Bauduer","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0225","doi-asserted-by":"crossref","first-page":"867380","DOI":"10.1155\/2009\/867380","article-title":"Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia","volume":"2009","author":"Guglielmelli","year":"2009","journal-title":"J Oncol"},{"key":"10.1016\/j.blre.2011.01.005_bb0230","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ijc.20793","article-title":"Bortezomib is an efficient agent in plasma cell leukemias","volume":"114","author":"Esparis-Ogando","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2011.01.005_bb0235","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1080\/10428190500520954","article-title":"Bortezomib is effective in primary plasma cell leukemia","volume":"47","author":"Finnegan","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.01.005_bb0240","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00277-005-0027-7","article-title":"Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib","volume":"85","author":"Grassinger","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0245","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.leukres.2007.11.010","article-title":"Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?","volume":"32","author":"Katodritou","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2011.01.005_bb0250","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1080\/10428190802290660","article-title":"Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy","volume":"49","author":"Al-Nawakil","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.01.005_bb0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1757-1626-2-121","article-title":"Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report","volume":"2","author":"Chan","year":"2009","journal-title":"Cases J"},{"key":"10.1016\/j.blre.2011.01.005_bb0260","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.20272","article-title":"Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature","volume":"78","author":"Saccaro","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2011.01.005_bb0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V114.22.532.532","article-title":"Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience","volume":"114","author":"Mahindra","year":"2009","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T04:06:39Z","timestamp":1592280399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X11000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0268960X11000063"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2011.01.005","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}